The influence of bexarotene, a selective agonist of the retinoid receptor X (RXR), and tazarotene, a selective agonist of the retinoid acid receptor (RAR), on bone metabolism in rats

被引:9
作者
Nowak, Beata [1 ]
Matuszewska, Agnieszka [1 ]
Filipiak, Jaroslaw [2 ]
Nikodem, Anna [2 ]
Merwid-Lad, Anna [1 ]
Piesniewska, Malgorzata [1 ]
Fereniec-Golebiewska, Lidia [1 ]
Kwiatkowska, Joanna [1 ]
Szelag, Adam [1 ]
机构
[1] Wroclaw Med Univ, Dept Pharmacol, Ul J Mikulicza Radeckiego 2, PL-50345 Wroclaw, Poland
[2] Wroclaw Univ Technol, Div Biomed Engn & Expt Mech, Wroclaw, Poland
来源
ADVANCES IN MEDICAL SCIENCES | 2016年 / 61卷 / 01期
关键词
Bone turnover; Retinoid receptor X (RXR); Retinoid acid receptor (RAR); Stress yield; VITAMIN-A; OVARIECTOMIZED RATS; IN-VITRO; PHARMACOKINETICS; DIFFERENTIATION; EXPRESSION; RESORPTION; FRACTURE; PATHWAY; HEALTH;
D O I
10.1016/j.advms.2015.09.001
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Purpose: The purpose of this study was to investigate the influence of selective agonists of the retinoid receptor X (RXR) and the retinoid acid receptor (RAR) on bone metabolism in rats. Methods: Thirty six male Wistar rats were divided into three groups: receiving bexarotene, or tazarotene, or to control group. Serum biochemical markers of bone turnover (osteocalcin - OC, tartrate resistant acid phosphatase 5 - TRACP5b and osteoprotegerin - OPG) and mechanical properties of bones were analyzed. Results: There was a significant decrease in the femur index value in groups receiving tazarotene and bexarotene on Day 14 (8% and 20% respectively, p = 0.0039). On Day 28, 14 days after discontinuation of tazarotene and bexarotene, the difference in femur indexes was still significant (4% for T1-6 and B1-6, p = 0.0270). In the bexarotene group an increase in mean plasma osteocalcin level and mean plasma TRACP5b level was detected. In the tazarotene group the mean osteocalcin level remained unchanged and the mean plasma TRACP5b level decreased. An increased yield stress was detected in groups receiving retinoids comparing to controls after 14 days of tazarotene and bexarotene administration. Conclusion: Although bexarotene and tazarotene administration caused decrease in the femur index, mechanisms responsible for that effect seem to be different. Our results suggest that bexaroten increases bone turnover. On the contrary, tazaroten seems to have inhibitory effect on bone turnover. A counter influence of selective RAR and RXR agonists on the bone turnover might be the reason for inconsistency in results from published research concerning the influence of retinoids on bone metabolism. (C) 2015 Medical University of Bialystok. Published by Elsevier Sp. z o.o. All rights reserved.
引用
收藏
页码:85 / 89
页数:5
相关论文
共 50 条
  • [21] No Influence of the CYP2C19-Selective Inhibitor Omeprazole on the Pharmacokinetics of the Dopamine Receptor Agonist Rotigotine
    Elshoff, Jan-Peer
    Cawello, Willi
    Andreas, Jens-Otto
    Braun, Marina
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2014, 3 (03): : 187 - 193
  • [22] Retinoid X Receptor-selective Signaling in the Regulation of Akt/Protein Kinase B Isoform-specific Expression
    AlSudais, Hamood
    Aabed, Kawther
    Nicola, William
    Dixon, Katherine
    Chen, Jihong
    Li, Qiao
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2016, 291 (06) : 3090 - 3099
  • [23] The Discovery of a Selective, Small Molecule Agonist for the Mas-Related Gene X1 Receptor
    Wroblowski, Berthold
    Wigglesworth, Mark J.
    Szekeres, Philip G.
    Smith, Graham D.
    Rahman, Shahzad S.
    Nicholson, Neville H.
    Muir, Alison I.
    Hall, Adrian
    Heer, Jag P.
    Garland, Stephen L.
    Coates, William J.
    JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (03) : 818 - 825
  • [24] Species-dependent metabolism of a novel selective α7 neuronal acetylcholine receptor agonist ABT-107
    Liu, Hong
    Deng, Xiaoqing
    Liu, Jinrong
    Liu, Ning
    Stuart, Patricia
    Xu, Hongyu
    Guan, Zhiwen
    Marsh, Kennan C.
    De Morais, Sonia M.
    XENOBIOTICA, 2013, 43 (09) : 803 - 816
  • [25] Estrogen receptor selective agonist ameliorates liver cirrhosis in rats by inhibiting the activation and proliferation of hepatic stellate cells
    Zhang, Bin
    Zhang, Cheng-Gang
    Ji, Lin-Hua
    Zhao, Gang
    Wu, Zhi-Yong
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 (03) : 747 - 755
  • [26] Prostaglandin E2 receptor EP4-selective agonist (ONO-4819) increases bone formation by modulating mesenchymal cell differentiation
    Ninomiya, Tadashi
    Hosoya, Akihiro
    Hiraga, Toru
    Koide, Masanori
    Yamaguchi, Kojiro
    Oida, Hiroji
    Arai, Yoshinori
    Sahara, Noriyuki
    Nakamura, Hiroaki
    Ozawa, Hidehiro
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2011, 650 (01) : 396 - 402
  • [27] Differential changes of retinoid-X-receptor (RXR alpha) and its RAR alpha and PML-RAR alpha partners induced by retinoic acid and cAMP distinguish maturation sensitive and resistant t(15;17) promyelocytic leukemia NB4 cells
    Duprez, E
    Lillehaug, JR
    Gaub, MP
    Lanotte, M
    ONCOGENE, 1996, 12 (11) : 2443 - 2450
  • [28] Unique Response Profile of Trabecular Meshwork Cells to the Novel Selective Glucocorticoid Receptor Agonist, GW870086X
    Stamer, W. Daniel
    Hoffman, Emely A.
    Kurali, Edit
    Krauss, Achim H.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (03) : 2100 - 2107
  • [29] Non-clinical evaluation of the metabolism, pharmacokinetics and excretion of S-777469, a new cannabinoid receptor 2 selective agonist
    Sekiguchi, Kazutaka
    Kanazu, Takushi
    Takeuchi, Masaharu
    Hasegawa, Hiroshi
    Yamaguchi, Yoshitaka
    XENOBIOTICA, 2014, 44 (01) : 48 - 58
  • [30] Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition
    Dummer, Reinhard
    Beyer, Marc
    Hymes, Kenneth
    Epping, Mirjam T.
    Bernards, Rene
    Steinhoff, Matthias
    Sterry, Wolfram
    Kerl, Helmut
    Heath, Karl
    Ahern, Janet D.
    Hardwick, James S.
    Garcia-Vargas, Jose
    Baumann, Katrin
    Rizvi, Syed
    Frankel, Stanley R.
    Whittaker, Sean J.
    Assaf, Chalid
    LEUKEMIA & LYMPHOMA, 2012, 53 (08) : 1501 - 1508